AU2020370867A1 - A cancer diagnostic - Google Patents

A cancer diagnostic Download PDF

Info

Publication number
AU2020370867A1
AU2020370867A1 AU2020370867A AU2020370867A AU2020370867A1 AU 2020370867 A1 AU2020370867 A1 AU 2020370867A1 AU 2020370867 A AU2020370867 A AU 2020370867A AU 2020370867 A AU2020370867 A AU 2020370867A AU 2020370867 A1 AU2020370867 A1 AU 2020370867A1
Authority
AU
Australia
Prior art keywords
cancer
markers
subject
expression level
determining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020370867A
Other languages
English (en)
Inventor
Richard LOBB
Andreas MÖLLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QIMR Berghofer Medical Research Institute
Original Assignee
Queensland Institute of Medical Research QIMR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904005A external-priority patent/AU2019904005A0/en
Application filed by Queensland Institute of Medical Research QIMR filed Critical Queensland Institute of Medical Research QIMR
Publication of AU2020370867A1 publication Critical patent/AU2020370867A1/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/54Determining the risk of relapse
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020370867A 2019-10-24 2020-10-26 A cancer diagnostic Pending AU2020370867A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904005 2019-10-24
AU2019904005A AU2019904005A0 (en) 2019-10-24 A cancer diagnostic
PCT/AU2020/051155 WO2021077181A1 (en) 2019-10-24 2020-10-26 A cancer diagnostic

Publications (1)

Publication Number Publication Date
AU2020370867A1 true AU2020370867A1 (en) 2022-06-09

Family

ID=75619520

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020370867A Pending AU2020370867A1 (en) 2019-10-24 2020-10-26 A cancer diagnostic

Country Status (8)

Country Link
US (1) US20220365089A1 (https=)
EP (1) EP4049027A4 (https=)
JP (1) JP7797382B2 (https=)
KR (1) KR20220092902A (https=)
CN (1) CN115380215B (https=)
AU (1) AU2020370867A1 (https=)
CA (1) CA3158472A1 (https=)
WO (1) WO2021077181A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116466085A (zh) * 2022-11-28 2023-07-21 中国人民解放军海军军医大学第三附属医院 一种四基因的生物标志物组合及其在肝癌治疗中的应用
WO2025050605A1 (en) * 2023-09-05 2025-03-13 The University Of Hong Kong Nidogen 1 as a diagnostic marker and therapeutic target of hepatocellular carcinoma, composition and methods thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140067001A (ko) * 2011-08-08 2014-06-03 카리스 라이프 사이언스 룩셈부르크 홀딩스, 에스.에이.알.엘. 생물지표 조성물 및 방법
CA2886607A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
CN106188244B (zh) * 2015-05-29 2019-12-27 王育民 抑制癌细胞活性的短肽治疗剂及含有它的医药组合物
EP3543701A4 (en) * 2016-10-28 2020-07-29 Japanese Foundation For Cancer Research BIOMARKER, METHOD OF SEARCHING FOR A GENE ASSOCIATED WITH A DISEASE, AND MARKER FOR KIDNEY CANCER
WO2018094469A1 (en) * 2016-11-24 2018-05-31 The Council Of The Queensland Institute Of Medical Research Determining a cancer prognosis
EP3716986A4 (en) * 2017-12-01 2022-02-09 Cornell University NANOPARTICLES AND VARIOUS EXOSOME SUBSETS FOR CANCER DETECTION AND TREATMENT
US12123058B2 (en) * 2018-01-25 2024-10-22 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer

Also Published As

Publication number Publication date
JP7797382B2 (ja) 2026-01-13
EP4049027A4 (en) 2024-02-07
US20220365089A1 (en) 2022-11-17
KR20220092902A (ko) 2022-07-04
CN115380215A (zh) 2022-11-22
WO2021077181A1 (en) 2021-04-29
CA3158472A1 (en) 2021-04-29
EP4049027A1 (en) 2022-08-31
CN115380215B (zh) 2026-03-17
JP2023500819A (ja) 2023-01-11

Similar Documents

Publication Publication Date Title
US20250116669A1 (en) Determining a Cancer Prognosis
US12209286B2 (en) Methods of diagnosing, determining the progression of, and treating a prostate cancer
JP7797382B2 (ja) がん診断
EP2449383A1 (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
KR20220170379A (ko) 암의 진단용 신규한 바이오마커 및 이의 용도
HK40084721A (en) A cancer diagnostic
WO2016201555A1 (en) Methods and compositions for the diagnosis of a thyroid condition
EP2966448B1 (en) Method for the prediction or prognosis of the response of a human subject suffering from cancer to treatment with an antagonist of the nk1 receptor
JP2014095643A (ja) 炎症性疾患治療薬のスクリーニング方法、並びに炎症性疾患の治療及び検査
JP2024523046A (ja) バイオマーカー及びそれらの使用
KR101940450B1 (ko) 비-소세포성 폐암 진단 융합 전사체 및 신규 전사체 마커
JP2020201278A (ja) 癌のバイオマーカーとしてのpd−ecgf
KR101516716B1 (ko) 간 섬유화 진단용 바이오마커 rorc
HK40049121A (en) Methods for detecting prostate cancer